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similar risk in those ages ≥75 years (4.43% vs. 4.37%; p =
0.89), whereas dabigatran 150 mg compared with warfarin
was associated with a lower risk of major bleeding in those
ages <75 years (2.12% vs. 3.04%; p < 0.001) and a trend
toward higher risk of major bleeding in those ages ≥75 years
(5.10% vs. 4.37%; p = 0.07). The interaction with age was
evident for extracranial bleeding, but not for intracranial
bleeding, with the risk of the latter being consistently
reduced with dabigatran compared with warfarin irrespective
of age.
Conclusions: In patients with atrial fibrillation at risk for
stroke, both doses of dabigatran compared with warfarin
have lower risks of both intracranial and extracranial bleed-
ing in patients ages <75 years. In those ages >75 years,
intracranial bleeding risk is lower, but extracranial bleeding
risk is similar or higher with both doses of dabigatran com-
pared with warfarin. 
Perspective: The Food and Drug Administration approved
only the higher dose of dabigatran, because while it had less
bleeding, the lower dose was associated with a 12% increase
in ischemic strokes compared to warfarin. There was a
twofold higher risk of major bleeding with dabigatran or
warfarin in patients with a creatinine clearance <50 ml/min
compared with a clearance >80 ml/min, which is consistent
with reports that renal function is a powerful predictor of
bleeding risk in patients treated with warfarin. They
approved a 75 mg twice daily schedule for persons with a
creatinine clearance of 15-30 ml/min and 150 mg for a
clearance >30 ml/min.
Summary written by: Melvyn Rubenfire, MD
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Arrhythmias
Risk of Bleeding With 2 Doses of Dabigatran
Compared With Warfarin in Older and Younger
Patients With Atrial Fibrillation: An Analysis of the
Randomized Evaluation of Long-Term
Anticoagulant Therapy (RE-LY) Trial
Eikelboom JW, Wallentin L, Connolly SJ, et al.
Circulation 2011;123:2363-2372.
Study Question: How do the risks of bleeding associated with
dabigatran compare at 150 versus 110 mg twice daily in
patients with atrial fibrillation? 
Methods: The RE-LY trial randomized 18,113 patients to
receive dabigatran 110 or 150 mg twice a day or warfarin
dose adjusted to an international normalized ratio of 2.0-3.0
for a median follow-up of 2.0 years. The main safety out-
come was major bleeding, and the primary efficacy outcome
was stroke or systemic embolism. 
Results: In both groups, mean age was 71.5 years, 64% were
male, mean blood pressure was 131/77 mm Hg, aspirin use
~39%, history of warfarin use ~50%, and CHADS2 score
was 2.1 ± 1.1. Compared with warfarin, dabigatran 110 mg
was associated with a lower risk of major bleeding (2.87%
vs. 3.57%; p = 0.002), whereas dabigatran 150 mg was asso-
ciated with a similar risk of major bleeding (3.31% vs.
3.57%; p = 0.32). Dabigatran 110 mg compared with war-
farin was associated with a lower risk of major bleeding in
patients ages <75 years (1.89% vs. 3.04%; p < 0.001) and a
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Methods: Between 2003 and 2008 at 25 French centers, 316
patients anatomically suitable for EVAR and considered
low/moderate risk for surgery were randomized to EVAR or
OSR. All aneurysms were >5 cm in diameter. Of the 299
patients suitable for analysis, 149 were randomized to OSR
and 150 to EVAR. Patient follow-up was 5 years. Primary
endpoints were death and any major adverse event (myocar-
dial infarction, stroke, permanent hemodialysis, major
amputation, paraplegia, or bowel infarction). Secondary end-
points included vascular re-interventions, sexual impairment,
buttock claudication, and incisional complications.
Results: Median study follow-up was 3 years. No difference
in cumulative survival or major adverse events was noted
between OSR and EVAR at 1 and 3 years (95.9 ± 1.6% vs.
93.2 ± 2.1% and 85.1 ± 4.5% vs. 82.4 ± 3.7%). In-hospital
mortality was 0.6% for OSR and 1.3% for EVAR. EVAR
was associated with higher re-intervention rates (2.4% vs.
16%) and a trend toward higher aneurysm-related mortality
(0.7% vs. 4%). Postoperative length of stay was significantly
less in the EVAR group. There was no difference in minor
complication rates, although the OSR group had more
minor cardiac and incision complications. Buttock claudica-
tion was more common in the EVAR group.
Conclusions: OSR is as safe as EVAR in patients with
low/moderate risk factors for surgery. OSR remains a more
durable repair option than EVAR. 
Perspective: EVAR is increasing becoming the first-line treat-
ment for all-comers with abdominal aortic aneurysm (AAA).
This study, although somewhat underpowered, suggests that
low/moderate-risk patients may benefit most from OSR
with its freedom from endoleaks and re-intervention, and
comes at a time when many surgeons are concerned that
OSR of AAAs is rapidly becoming a lost art.
Summary written by: John E. Rectenwald, MD, MS
Transcatheter Versus Surgical Aortic-Valve
Replacement in High-Risk Patients
Smith CR, Leon MB, Mack MJ, et al., on behalf of the PARTNER
Trial Investigators.
N Engl J Med 2011;364:2187-2198.
Study Question: What are the outcomes for the high-risk sub-
group of patients in the PARTNER trial who were still
candidates for surgical valve replacement and were randomly
assigned to undergo either transcatheter or surgical replace-
ment of the aortic valve? 
Methods: At 25 centers, the investigators randomly assigned
699 high-risk patients with severe aortic stenosis to undergo
either transcatheter aortic valve replacement with a balloon-
expandable bovine pericardial valve (either a transfemoral or
a transapical approach) or surgical replacement. The primary
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Landiolol Hydrochloride for Prevention of Atrial
Fibrillation After Coronary Artery Bypass Grafting:
New Evidence From the PASCAL Trial
Sesazi A, Minami K, Nakai T, et al.
J Thorac Cardiovasc Surg 2011;141:1478-1487.
Study Question: Does landiolol prevent atrial fibrillation (AF)
after coronary artery bypass grafting (CABG)? 
Methods: One hundred and forty patients (mean age 67
years) undergoing CABG were randomized in a blinded
fashion to receive either landiolol, 2 mcg/kg/min (n = 70) or
saline (n = 70), for 48 hours after the operation. Continuous
electrocardiographic monitoring was performed for 1 week.
The primary endpoint was AF lasting >5 minutes during
the first postoperative week.  
Results: Postoperative AF occurred in significantly fewer
patients in the landiolol group (10%) than placebo (34.3%).
The mean postoperative blood pressures were similar. The
mean heart rate was significantly lower in the landiolol
group, but no patient developed excessive bradycardia. The
mean creatine kinase-MB, troponin, and C-reactive protein
levels were significantly lower in the landiolol group. The
cost of hospitalization was significantly lower in the landi-
olol group ($35,680) than in placebo ($39,980).  
Conclusions: Landiolol prevents AF after CABG. 
Perspective: Landiolol is an ultrashort-acting beta1-selective
beta-blocker available only in Japan. It less often causes
hypotension. In this study, it appears to have reduced the
incidence of post-CABG AF by reducing ischemia-reperfu-
sion injury, inflammation, and sympathetic tone. Drugs
available in the United States that have been demonstrated to
prevent post-CABG AF include oral beta-blockers, sotalol,
and amiodarone.
Summary written by: Fred Morady, MD
Cardiovascular Surgery
A Randomized Controlled Trial of Endovascular
Aneurysm Repair Versus Open Surgery for
Abdominal Aortic Aneurysms in Low- to Moderate-
Risk Patients
Becquemin JP, Pillet JC, Lescalie F, et al.
J Vasc Surg 2011;53:1167-1173.
Study Question: Does endovascular abdominal aneurysm
repair (EVAR) confer a survival advantage over open surgi-
cal repair (OSR) when applied to low/moderate-risk
patients? 
the variable ACS status and the year of study, use of on-
pump surgery, patient urgency status, and use of
concomitant antiplatelet agents. 
Results: Although mortality is increased in CL versus NC
(OR, 1.6; 95% confidence interval [CI], 1.30-1.96), it is
influenced by the ACS status and case urgency in these
mainly nonrandomized studies. In ACS patients, there is no
significant difference in mortality (OR, 1.44; 95% CI, 0.97-
2.1) or postoperative MI (OR, 0.57; 95% CI, 0.31-1.07)
and stroke rates (OR, 1.23; 95% CI, 0.66-2.29). Combined
major adverse cardiovascular events (stroke, MI, and death)
were not different in the two groups (OR, 1.10; 95% CI,
0.87-1.41). Reoperation rates are elevated on clopidogrel but
have reduced over time, and were not different in ACS
patients (OR, 1.5; 95% CI, 0.88-2.54). 
Conclusions: ACS patients requiring urgent CABG proceed
with surgery without delay for a clopidogrel-free period.
Perspective: This meta-analysis suggests that continuing dual
antiplatelet therapy until the day of CABG reduces the risk
of recurrent ischemic events in ACS patients and reduces
MI postoperatively. These data demonstrate the need for a
randomized clinical trial assessing different discontinuation
times prior to CABG to definitively answer the question.
Meanwhile, the evidence appears to suggest that many ACS
patients can undergo CABG safely with recent clopidogrel
exposure in expert hands.
Summary written by: Debabrata Mukherjee, MD
General
Gender Differences in the Prognostic Value of
Exercise Treadmill Test Characteristics
Daugherty SL, Magid DJ, Kikla JR, et al.
Am Heart J 2011;161:908-914.
Study Question: Does the prognostic significance of exercise
treadmill testing (ETT) variables differ by gender?
Methods: The study population from the clinical registry of
Kaiser Permanente of Colorado was used for this analysis.
Members >18 years referred for ETT between July 2001 and
June 2004 were included. All ETTs were symptom-limited
testing with the majority using a Bruce protocol. Data col-
lected included occurrence of symptoms, ST-segment
deviations, exercise capacity heart rate recovery, and
chronotropic incompetence. The primary outcomes of inter-
est were all-cause mortality and hospitalization for myocardial
infarction (MI) over a mean follow-up of 3.2 years.
Multivariate models were adjusted for patient and stress test
characteristics, and were stratified by gender to determine the
relationship between ETT variables and outcomes.  
endpoint was death from any cause at 1 year. The primary
hypothesis was that transcatheter replacement is not inferior
to surgical replacement. 
Results: The rates of death from any cause were 3.4% in the
transcatheter and 6.5% in the surgical group at 30 days, and
24.2% and 26.8%, respectively, at 1 year (p = 0.001 for non-
inferiority). The rates of major stroke were 3.8% in the
transcatheter and 2.1% in the surgical group at 30 days, and
5.1% and 2.4%, respectively, at 1 year. At 30 days, major
vascular complications were significantly more frequent with
transcatheter replacement (11.0% vs. 3.2%); adverse events
that were more frequent after surgical replacement included
major bleeding (9.3% vs. 19.5%) and new-onset atrial fibril-
lation (8.6% vs. 16.0%). More patients undergoing
transcatheter replacement had an improvement in symptoms
at 30 days, but by 1 year, there was not a significant
between-group difference.
Conclusions: In high-risk patients with severe aortic stenosis,
transcatheter and surgical procedures for aortic valve
replacement had similar rates of survival at 1 year.
Perspective: Overall, these findings indicate that the
transcatheter procedure is an alternative to surgical replace-
ment in a well chosen, high-risk subgroup of patients with
aortic stenosis, and recommendations to individual patients
must balance the known risks of open heart surgery against
the transcatheter approach, which may have different risks,
particularly with respect to the approximate doubling in the
rate of all new neurologic events, including major stroke.
Summary written by: Debabrata Mukherjee, MD
Safety of Clopidogrel Being Continued Until the
Time of Coronary Artery Bypass Grafting in
Patients With Acute Coronary Syndrome: A Meta-
Analysis of 34 Studies
Nijjer SS, Watson G, Athanasiou T, Malik IS.
Eur Heart J 2011;May 24:[Epub ahead of print].
Study Question: What is the risk of mortality, reoperation,
perioperative myocardial infarction (MI), and stroke in the
acute coronary syndrome (ACS) population undergoing
coronary artery bypass grafting (CABG) while on clopido-
grel?
Methods: Thirty-four studies with 22,584 patients undergo-
ing CABG were assessed. Patients with recent clopidogrel
exposure (CL) were compared with those without recent
clopidogrel (NC). Uni- and multivariate meta-regression
was performed for the main outcomes of mortality, reopera-
tion, postoperative MI, and stroke using the logarithm of
the odds ratio (OR) as the dependent variable. Interaction
analysis was performed creating interaction terms between
JACC Vol. 58, No. 6, 2011
August 2, 2011:553-60
Eagle, Cannon 555
Scanning the Literature
Results: A total of 9,569 patients were included; 46.8% were
women. Overall, exercise capacity and heart rate recovery
were significantly associated with all-cause death. Exercise
capacity, chest pain, and ST-segment deviations were signif-
icantly associated with subsequent MI. The relationship
between ETT variables and outcomes was similar between
men and women, except for abnormal exercise capacity,
which had a significantly stronger association with death in
men (hazard ratio [HR], 2.89), but not women (HR, 0.99).
In contrast, chronotropic incompetence had a significantly
stronger relationship with MI for women (HR, 2.79) than
men (HR, 1.29). 
Conclusions: Several traditional ETT variables had similar
prognostic value in both men and women. However, exercise
capacity was more prognostically important in men, and
chronotropic incompetence was more important in women. 
Perspective: It is known that gender differences exist for ETT
as a diagnostic tool to detect coronary artery disease; however,
variables such as chronotropic incompetence which have prog-
nostic importance, have not been well studied in terms of
gender. Further understanding of such variables will assist in
improving diagnostic information for women with heart dis-
ease and those at risk for MI.
Summary written by: Elizabeth A. Jackson, MD
Treatment and Outcomes in Patients With
Myocardial Infarction Treated With Acute β-Blocker
Therapy: Results From the American College of
Cardiology’s NCDR®
Kontos MC, Diercks DB, Ho PM, Wang TY, Chen AY, Roe MT.
Am Heart J 2011;161:864-870.
Study Question: What is the association between beta-blocker
(BB) use and in-hospital outcomes stratified by type of
myocardial infarction (MI) and number of risk factors for car-
diogenic shock? 
Methods: The investigators examined acute (≤24 hours) BB
use in 34,661 patients with ST-elevation MI (STEMI) and
non–STEMI (NSTEMI) included in the NCDR®
ACTION Registry®-GWTG™ (291 US hospitals) between
January 2007 and June 2008. They analyzed the use and
impact of BBs stratified by variables associated with
increased risk for shock specified in the recent guidelines:
age >70 years, symptoms >12 hours (STEMI), systolic blood
pressure <120 mm Hg, and heart rate >110 bpm on presen-
tation. 
Results: At least one high-risk variable was found in 45% of
STEMI and 63% of NSTEMI patients. In-hospital compli-
cations including cardiogenic shock, mortality, and the
composite outcome of shock or mortality were significantly
increased, with more shock risk factors in both STEMI and
NSTEMI patients. Very early use in the emergency depart-
ment was associated with a significantly increased risk of
shock for both STEMI and NSTEMI patients compared to
patients treated later, but within 24 hours. 
Conclusions: Risk factors for shock are common in STEMI
and NSTEMI patients treated with early BBs. 
Perspective: The study found that most patients with STEMI
or NSTEMI who were treated with acute BB treatment had at
least one risk factor for cardiogenic shock, as defined by cur-
rent guidelines. The data support current guidelines, which
recommend that caution be used when giving BBs to high-risk
patients early during the initial acute care period, and waiting
for stabilization before starting a BB appears prudent.
Summary written by: Debabrata Mukherjee, MD
Association Between Ambulance Diversion and
Survival Among Patients With Acute Myocardial
Infarction
Shen YC, Hsia RY.
JAMA 2011;305:2440-2447.
Study Question: What is the association between ambulance
diversion hours and mortality rates among patients with acute
myocardial infarction (AMI)?
Methods: This was a case-crossover design of 13,860
Medicare patients with AMI from 508 zip codes within four
California counties. Data included 100% Medicare claims
that covered admissions between 2000 and 2005, linked with
date of death until 2006, and daily ambulance diversion logs
from the four counties. Among the hospital universe, 149
emergency departments (EDs) were identified as the nearest
ED. The main outcome measure was the percentage of
patients with AMI who died within 7 days, 30 days, 90 days,
9 months, and 1 year from admission (when their nearest
ED was not on diversion and when that same ED was
exposed to <6, 6 to <12, and ≥12 hours of diversion out of 24
hours on the day of admission).   
Results: The mean daily diversion duration was 7.9  hours.
Based on analysis of 11,625 patients admitted to the ED,
and whose nearest ED had at least three diversion exposure
levels (3,541, 3,357, 2,667, and 2,060 patients for no expo-
sure, exposure to <6, 6 to <12, and ≥12 hours of diversion,
respectively), there were no statistically significant differences
in mortality rates between no diversion and exposure to less
than 12 hours of diversion. Exposure to 12 or more hours of
diversion was associated with higher 30-day mortality versus
no diversion status (unadjusted mortality rate, 19% vs. 15%),
higher 90-day mortality (26% vs. 22%), higher 9-month
mortality (33% vs. 28%), and higher 1-year mortality (35%
vs. 29%). 
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This study reaffirms the importance of LBBB and underscores
the significance of RBBB on initial electrocardiogram in the
initial risk stratification of patients presenting with angina.
Summary written by: Debabrata Mukherjee, MD
Interventional
A New Protocol Using Sodium Bicarbonate for the
Prevention of Contrast-Induced Nephropathy in
Patients Undergoing Coronary Angiography
Motohiro M, Kamihata H, Tsujimoto S, et al.
Am J Cardiol 2011;107:1604-1608.
Study Question: What is the relative efficacy of sodium bicar-
bonate versus normal saline in preventing contrast-induced
nephropathy (CIN)? 
Methods: The authors randomized 155 patients with a
glomerular filtration rate (GFR) <60 ml/min/1.73 m2 who
were undergoing coronary angiography to sodium chloride
plus sodium bicarbonate (bicarbonate group, n = 78) or
sodium chloride alone (chloride group, n = 77). All patients
received normal saline 12 hours before and after the proce-
dure. Infusion of sodium bicarbonate at 1 ml/kg/h was
started 3 hours before and continued 6 hours after coronary
angiography. CIN was defined as either a 25% increase in
serum creatinine or an absolute increase of ≥0.5 mg/dl within
2 days of the procedure. 
Results: There was no difference in the baseline GFR
between the two groups. Randomization to bicarbonate was
associated with a higher GFR compared with sodium chlo-
ride on day 2 (45.8 ± 13.4 vs. 40.9 ± 14.6 ml/min/1.73 m2)
and at 1 month (49.5 ± 14.7 vs. 43.7 ± 15.5 ml/min/1.73
m2). Randomization to bicarbonate was associated with a
reduction in incidence of CIN (13% vs. 2.6%). 
Conclusions: Randomization to bicarbonate is associated with
a reduction in the incidence of CIN in patients undergoing
angiography. 
Perspective: Multiple studies comparing sodium bicarbonate
versus normal saline-based hydration for prophylaxis of CIN
indicate a reduction in CIN with bicarbonate. There has,
however, been no evidence of reduction in harder endpoints
with sodium bicarbonate-based hydration, and most larger
studies found no difference in outcome between the two
strategies. Prevention of CIN requires adequate hydration
with either saline or sodium bicarbonate and minimization of
contrast volume.
Summary written by: Hitinder S. Gurm, MBBS
Conclusions: At least 12 hours of diversion by the nearest ED
was associated with increased 30-day, 90-day, 9-month, and
1-year mortality. 
Perspective: This analysis suggests that lengthy ED diversions
are associated with higher mortality rates among patients with
a time-sensitive condition such as AMI. These findings point
to the societal need for more targeted interventions to appro-
priately distribute system-level resources in such a way to
decrease crowding and diversion, so that patients with time-
sensitive conditions are not adversely affected.
Summary written by: Debabrata Mukherjee, MD
Long-Term Cardiovascular Outcomes in Patients
With Angina Pectoris Presenting With Bundle
Branch Block
Bansilal S, Aneja A, Mathew V, et al.
Am J Cardiol 2011;107:1565-1570.
Study Question: What is the short- and long-term prognostic
significance of bundle branch block (BBB) in patients present-
ing to the emergency department with angina? 
Methods: The Olmsted County Chest Pain Study is a com-
munity-based cohort of 2,271 patients presenting to three
Olmsted County emergency departments with angina from
1985 through 1992. Patients were followed for major
adverse cardiovascular events (MACE) including death,
myocardial infarction, stroke, and revascularization at 30
days and over a median follow-up of 7.3 years, and for mor-
tality through a median of 16.6 years. Cox models were used
to estimate associations between BBB and cardiovascular
outcomes. 
Results: Mean age on presentation was 63 years, and 58%
were men. MACE at 30 days occurred in 11% with right
BBB (RBBB), 8.8% with left BBB (LBBB), and 6.4% with-
out BBB (p = 0.17). Patients with BBB were at higher risk
for MACE (RBBB, hazard ratio [HR] 1.85; LBBB, HR
2.04) compared to those without BBB. Over a median of
16.6 years, the two BBB groups had lower survival rates
than patients without BBB (RBBB, HR 2.19; LBBB, HR
3.32), but after adjustment for multiple risk factors, an
increased risk of mortality for LBBB remained significant. 
Conclusions: The appearance of LBBB or RBBB in patients
presenting with angina predicts adverse long-term cardiovas-
cular outcomes compared to patients without BBB. 
Perspective: In this study, the pattern of RBBB on presenting
electrocardiogram predicted poor cardiovascular outcomes over
7 years and greater mortality of 15 years compared to those
without BBB, but these differences were largely attributable to
a greater burden of associated risk factors. 
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Association of Door-In to Door-Out Time With
Reperfusion Delays and Outcomes Among Patients
Transferred for Primary Percutaneous Coronary
Intervention
Wang TY, Nallamothu BK, Krumholz HM, et al.
JAMA 2011;305:2540-2547.
Study Question: What is the relationship between a door-in to
door-out (DIDO) time of 30 minutes or less, time to reper-
fusion, and patient outcomes? 
Methods: This was a retrospective cohort study of 14,821
patients with ST-segment elevation myocardial infarction
(STEMI) transferred to 298 STEMI receiving centers for
primary percutaneous coronary intervention (PCI) in the
NCDR® ACTION Registry®–GWTG™ between January
2007 and March 2010. The main outcome measures were
factors associated with a DIDO time greater than 30 min-
utes, overall door-to-balloon (DTB) times, and risk-adjusted
in-hospital mortality. 
Results: Median DIDO time was 68 minutes, and only 1,627
patients (11%) had DIDO times of 30 minutes or less.
Significant factors associated with a DIDO time greater
than 30 minutes included older age, female sex, off-hours
presentation, and nonemergency medical services transport
to the first hospital. Patients with a DIDO time of 30 min-
utes or less were significantly more likely to have an overall
DTB time of 90 minutes or less compared with patients
with DIDO times greater than 30 minutes (60%; 95% con-
fidence interval [CI], 57%-62% vs. 13%, 95% CI,
12%-13%). Among patients with DIDO times greater than
30 minutes, only 0.6% (95% CI, 0.5%-0.8%) had an
absolute contraindication to fibrinolysis. Observed in-hospi-
tal mortality was significantly higher among patients with
DIDO times greater than 30 minutes versus patients with
less (5.9%; 95% CI, 5.5%-6.3% vs. 2.7%; 95% CI, 1.9%-
3.5%; adjusted odds ratio for in-hospital mortality, 1.56;
95% CI, 1.15-2.12). 
Conclusions: A DIDO time of 30 minutes or less was associ-
ated with shorter reperfusion delays and lower in-hospital
mortality. 
Perspective: DIDO time is a new performance measure that
assesses the timeliness and quality of initial care for patients
who require interhospital transfer for primary PCI. Overall,
the study suggests that attention and improvement of this
performance measure will likely translate into improvement
in the timeliness of primary PCI and clinical outcomes for
transferred STEMI patients.
Summary written by: Debabrata Mukherjee, MD
Myocardial Infarction After Carotid Stenting and
Endarterectomy: Results From the Carotid
Revascularization Endarterectomy Versus Stenting
Trial
Blackshear JL, Cutlip DE, Roubin GS, et al.; on behalf of the
CREST Investigators.
Circulation 2011;123:2571-2578.
Study Question: What is the incidence and implication of
myocardial infarction (MI) in patients undergoing carotid
revascularization? 
Methods: The authors reported the incidence and implica-
tions of MI in patients who underwent carotid artery
stenting (CAS) or carotid endarterectomy (CEA) in the
CREST trial. Cardiac biomarkers and electrocardiograms
(ECGs) were performed before and 6-8 hours after carotid
revascularization, and if there was clinical evidence of
ischemia. MI was defined as biomarker elevation plus either
chest pain or ECG evidence of ischemia. They also evalu-
ated the subgroup who had biomarker elevation without
chest pain or ECG abnormality (isolated biomarker eleva-
tion). 
Results: There were 14 MIs among patients randomized to
CAS and 28 MIs for CEA (hazard ratio [HR], 0.50; 95%
confidence interval [CI], 0.26-0.94; p = 0.032). Of the MIs,
one occurred after randomization but before the index pro-
cedure, 29 occurred within 24 hours of the initial carotid
revascularization procedure, nine occurred between 2 and 7
days after carotid revascularization, and three occurred
between 8 and 30 days after carotid revascularization. There
were two ST elevation MIs, with one in each arm. Twenty
patients had biomarker elevation only (8 CAS and 12 CEA;
HR, 0.66; 95% CI, 0.27-1.61). The median biomarker ele-
vation was 14 times the upper limit of normal compared
with 40 times  for an adjudicated MI. Compared with
patients without biomarker elevation, an increase in long-
term mortality was seen with MI (HR, 3.40; 95% CI,
1.67-6.92) or isolated biomarker elevation (HR, 3.57; 95%
CI, 1.46-8.68). 
Conclusions: Patients undergoing CAS are at a lower risk of MI
compared with CEA. Patients who suffer a postprocedural MI
have an exaggerated hazard of long-term mortality. 
Perspective: The lower risk of MI with CAS compared with
CEA has been a consistent finding in multiple studies.
There was no difference in the long-term risk of death
between patients treated with either strategy, and the choice
of revascularization should be determined by careful consid-
eration of a given patient’s risk with either procedure and
informed patient choice.
Summary written by: Hitinder S. Gurm, MBBS
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Television Viewing and Risk of Type 2 Diabetes,
Cardiovascular Disease, and All-Cause Mortality: A
Meta-Analysis
Grøntved A, Hu FB.
JAMA 2011;305:2448-2455.
Study Question: Is prolonged television (TV) viewing associ-
ated with increased morbidity and mortality? 
Methods: This meta-analysis included articles identified
through searches of the MEDLINE database from 1970 to
March 2011, and the EMBASE database from 1974 to
March 2011. For inclusion, articles had to be published in
English, have a prospective study design (including cohort,
case-cohort, and nested case-control), and a study population
which was apparently healthy at baseline. 
Results: Eight studies were included. Four reported results on
type 2 diabetes, which included 175,938 individuals and 6,428
incident cases during 1.1 million person-years of follow-up.
Four studies reported on fatal or nonfatal cardiovascular dis-
ease (34,253 individuals; 1,052 incident cases). Three studies
reported on all-cause mortality (26,509 individuals; 1,879
deaths during 202,353 person-years of follow-up). The pooled
relative risks per 2 hours of TV viewing per day were 1.20
(95% confidence interval [CI], 1.14-1.27) for type 2 diabetes,
1.15 (95% CI, 1.06-1.23) for fatal or nonfatal cardiovascular
disease, and 1.13 (95% CI, 1.07-1.18) for all-cause mortality.
The associations between time spent viewing TV and risk of
type 2 diabetes and cardiovascular disease were linear; how-
ever, the risk of all-cause mortality appeared to increase with
TV viewing of >3 hours per day. The estimated absolute risk
differences per every 2 hours of TV viewing per day were 176
cases of type 2 diabetes per 100,000 individuals per year, 38
cases of fatal cardiovascular disease per 100,000, and 104
deaths for all-cause mortality per 100,000.
Conclusions: Prolonged TV viewing is associated with increased
risk of type 2 diabetes, cardiovascular disease, and all-cause
mortality. 
Perspective: Given the prevalence of TV watching among
residents of industrialized countries, clinicians are recom-
mended to advise patients regarding the risk of sedentary
behaviors such as TV watching.
Summary written by: Elizabeth A. Jackson, MD
Survival Among High-Risk Patients After Bariatric
Surgery
Maciejewski ML, Livingston EH, Smith VA, et al.
JAMA 2011;305:2419-2426.
Study Question: What is the association of bariatric surgery and
survival for older men?  
Methods: This was a retrospective cohort study of bariatric
surgery programs in Veterans Affairs medical centers.
Mortality was examined for 850 veterans who had bariatric
surgery in January 2000 to December 2006 (mean age 49.5
years, mean body mass index [BMI] 47.4) and 41,244 non-
surgical controls (mean age 54.7 years, mean BMI 42.0)
from the same 12 Veteran Integrated Service Networks;
mean follow-up was 6.7 years. Four Cox proportional haz-
ards models were assessed: unadjusted and controlled for
baseline covariates on unmatched and propensity-matched
cohorts. The main outcome measure was all-cause mortality. 
Results: Among patients who had bariatric surgery, the 1-,
2-, and 6-year crude mortality rates were, respectively, 1.5%,
2.2%, and 6.8% compared with 2.2%, 4.6%, and 15.2% for
nonsurgical controls. In unadjusted Cox regression, bariatric
surgery was associated with reduced mortality (hazard ratio
[HR], 0.64; 95% confidence interval [CI], 0.51-0.80). After
covariate adjustment, bariatric surgery remained associated
with reduced mortality (HR, 0.80; 95% CI, 0.63-0.995). In
analysis of 1,694 propensity-matched patients, bariatric sur-
gery was no longer significantly associated with reduced
mortality in unadjusted (HR, 0.83; 95% CI, 0.61-1.14) and
time-adjusted (HR, 0.94; 95% CI, 0.64-1.39) Cox regres-
sions.
Conclusions: The use of bariatric surgery compared with usual
care was not associated with decreased mortality in severely
obese older patients. 
Perspective: Even though bariatric surgery may not be associ-
ated with reduced mortality among older male patients, many
may still choose it, given the strong evidence for significant
reductions in body weight and comorbidities such as diabetes
and improved quality of life. Additional prospective studies
with longer-term follow-up and careful selection of surgical
and nonsurgical cohorts are needed to ascertain the true sur-
vival advantage of bariatric surgery.
Summary written by: Debabrata Mukherjee, MD
JACC Vol. 58, No. 6, 2011
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Sensitive Cardiac Troponin T Assay and the Risk of
Incident Cardiovascular Disease in Women With
and Without Diabetes Mellitus: The Women’s Health
Study
Everett BM, Cook NR, Magnone, MC, et al.
Circulation 2011;123:2811-2818.
Study Question: Are very low levels of cardiac troponin T
(cTnT) predictive of adverse cardiovascular (CV) events in
women without previous CV disease (CVD)? 
Methods: The relationship between baseline cTn and incident
CVD events among diabetic and nondiabetic participants in
the Women’s Health Study (median follow-up, 12.3 years)
was evaluated. All diabetic women with blood specimens were
included in a cohort study (n = 512 diabetic women, n = 65
events), and nondiabetic women were sampled for inclusion in
a case-cohort analysis (n = 564 comprising the subcohort, n =
479 events). 
Results: High-sensitivity cTnT was detectable (≥0.003 μg/L)
in 45.5% of diabetic women and 30.3% of nondiabetic
women (p < 0.0001). In models adjusted for traditional risk
factors, detectable high-sensitivity cTnT was associated
with subsequent CVD (myocardial infarction, stroke, car-
diovascular death) in diabetic women (adjusted hazard ratio
[HR], 1.79; p = 0.036), but not nondiabetic women (HR,
1.13; p = 0.46). The effect in diabetic women was driven by
a threefold increase in CVD death that was not observed in
nondiabetic women.  
Conclusions: Detectable levels of cTnT are associated with total
CVD and CVD death in women with diabetes mellitus. 
Perspective: The current study expands on previous studies by
demonstrating that detectable cTnT levels are associated with
adverse outcomes in a female population as well. However,
the association was only observed in women with diabetes.
The reason for lack of association of cTnT in nondiabetic
woman is unclear and will require further analysis. Additional
studies are also necessary to determine the underlying mecha-
nisms by which these low (but elevated) levels of cTnT are
generated and how this information might be used to guide
preventive strategies.
Summary written by: Daniel T. Eitzman, MD
Smoking, Smoking Status, and Risk for
Symptomatic Peripheral Artery Disease in Women:
A Cohort Study
Conen D, Everett BM, Kurth T, et al.
Ann Intern Med 2011;154:719-726.
Study Question: How are current smoking status, cumulative
smoking exposure, and/or smoking cessation associated
with incident symptomatic peripheral arterial disease
(PAD) in women? 
Methods: This was a prospective cohort study of US female
health care professionals enrolled in the Women’s Health
Study. Women with no apparent cardiovascular disease at
baseline were followed for a median of 12.7 years. Current
smokers were queried about the average number of cigarettes
they smoked per day at study entry. Participants were asked
how many total years they had smoked and the number of
cigarettes they had smoked per day across eight age cate-
gories, ranging from younger than 15 years to 70 years or
older. Participants answered the same questionnaire at
months 12, 24, 48, 72, and 96; at the end of the randomized
portion of the study; and three more times during the obser-
vational follow-up study. Participants were surveyed annually
for health outcomes including symptomatic PAD including
intermittent claudication, and PAD interventions. 
Results: A total of 39,825 women were included, of which
20,336 women were never smokers, 14,263 were former
smokers, and 1,967 smoked <15 cigarettes per day, and
3,259 smoked 15 or more cigarettes per day. During fol-
low-up, 178 confirmed PAD events were identified. Across
the four smoking categories (never, former, <15 ciga-
rettes/day, and ≥15 cigarettes/day), age-adjusted incidence
rates were 0.12, 0.34, 0.95, and 1.63 per 1,000 person-
years of follow-up, respectively. A strong dose–response
relationship was observed for lifetime exposure. Compared
with current smokers, the adjusted HRs for fewer than 10
years of smoking, 10-20 years of smoking, more than 20
years of smoking, or lifelong abstinence were 0.39 (95%
CI, 0.24-0.66), 0.28 (95% CI, 0.17-0.46), 0.16 (95% CI,
0.10-0.26), and 0.08 (95% CI, 0.05-0.12), respectively. 
Conclusions: Among initially healthy women, smoking is a sig-
nificant risk factor for symptomatic PAD. Smoking cessation
reduced the risk for PAD; however, increased occurrence of
PAD persisted even among former smokers who maintained
abstinence. 
Perspective: These data suggest that although smoking cessa-
tion reduced the risk for PAD, being a lifelong nonsmoker
carries the lowest risk of symptomatic PAD. Given the rates
of smoking among young adults, including women, efforts to
prevent initiation of smoking carry significant public health
ramifications 
Summary written by: Elizabeth A. Jackson, MD
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